STAT3
also: Signal Transducer and Activator of Transcription 3, STAT3 pathway
Signal Transducer and Activator of Transcription 3 — a transcription factor central to the JAK/STAT cascade and mitochondrial peptide signalling.
STAT3 is a transcription factor that shuttles between the cytoplasm and nucleus, becoming active when phosphorylated on tyrosine-705 by Janus kinases (JAKs). Once phosphorylated, STAT3 dimerises, translocates to the nucleus, and drives expression of genes involved in cell survival, proliferation, and immune modulation.
Why it matters in peptide research
STAT3 sits at the convergence of dozens of upstream signals — interleukins, growth factors, and, critically for peptide researchers, mitochondria-derived peptides such as Humanin. Humanin binds the tripartite receptor complex consisting of CNTFR, WSX-1, and gp130, which triggers JAK1/JAK2 phosphorylation and subsequent STAT3 activation. This makes STAT3 one of the key mechanistic bridges explaining Humanin's cytoprotective effects in neuronal and cardiomyocyte models.
Beyond Humanin, STAT3 is chronically over-activated in many cancers, which gives the pathway a dual character in the literature: it is pro-survival in healthy tissues under acute stress but pathological when constitutively switched on. Peptide research that modulates STAT3 therefore demands careful dose-and-context framing to avoid conflating beneficial acute signalling with oncogenic constitutive activity.
Understanding STAT3 also clarifies why many peptides with immune-modifying properties show tissue-selective effects. Because STAT3 target genes vary by cell type — depending on chromatin accessibility and co-factor availability — the same upstream activation can produce anti-inflammatory outcomes in macrophages while promoting differentiation in stem-cell niches.
Peptides / stacks that act on this
- Humanin — binds gp130-containing receptor complex to activate JAK/STAT3; primary mitochondrial peptide studied in this pathway
Common misconceptions
STAT3 activation is often labelled uniformly "pro-cancer" in lay commentary, but acute, transient STAT3 phosphorylation is a normal feature of tissue repair and immune resolution. The pathological variant is chronic, ligand-independent STAT3 activity driven by somatic mutations or persistent upstream kinase activation — a fundamentally different biological state from the short-lived receptor-mediated signalling that research peptides engage.